Matches in Wikidata for { <http://www.wikidata.org/entity/Q59328394> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q59328394 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59328394 description "wetenschappelijk artikel" @default.
- Q59328394 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q59328394 name "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 name "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 type Item @default.
- Q59328394 label "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 label "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 prefLabel "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 prefLabel "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 P1433 Q59328394-297946F2-D27E-48DC-986A-EDB2F69BC5B4 @default.
- Q59328394 P1476 Q59328394-F4D5BC97-DDD6-4D7C-9CB3-69732016CEE8 @default.
- Q59328394 P2093 Q59328394-0D7E79A4-6D1C-4C3E-AC9A-B0E0FD15E09C @default.
- Q59328394 P2093 Q59328394-3BC940D4-0DDD-4B68-8F66-406F3C4AA9CD @default.
- Q59328394 P2093 Q59328394-5C6CE0CC-6F27-4982-9E5D-4A4473B914CC @default.
- Q59328394 P2093 Q59328394-7D50FB5D-7372-4FDD-B0BF-AFC97202B02F @default.
- Q59328394 P2093 Q59328394-95D36839-6E14-44A9-8E7F-131907E3566B @default.
- Q59328394 P2093 Q59328394-9BC64AF1-A258-42A1-8116-762E376244DC @default.
- Q59328394 P2093 Q59328394-B7097F6F-1277-4423-812B-FC4CD62AEF19 @default.
- Q59328394 P2093 Q59328394-BD2BED0D-3931-4A9E-B677-8B271566181B @default.
- Q59328394 P2093 Q59328394-C4AE7690-B6C4-4A51-8C49-D9DC956C823A @default.
- Q59328394 P2093 Q59328394-F02B0386-9DAE-43B5-9862-BE2BC63BF0DA @default.
- Q59328394 P2093 Q59328394-FAA69C0B-785C-40BC-9BD4-EFFDE3D58CEA @default.
- Q59328394 P2093 Q59328394-FF44D75E-C791-42AB-A287-18E256105E49 @default.
- Q59328394 P275 Q59328394-9bdb3e5b-9844-4512-90b7-307964e706c8 @default.
- Q59328394 P304 Q59328394-4DA7A63E-FE07-42DF-BA2B-2CC4A82870CC @default.
- Q59328394 P31 Q59328394-774A4BBA-3C19-40F1-A00D-111B946FC90D @default.
- Q59328394 P356 Q59328394-B4F61C56-3FD8-4F9E-B626-3A6A5F9BC972 @default.
- Q59328394 P433 Q59328394-C8866F81-C221-4A91-9FE6-01D4C2C39231 @default.
- Q59328394 P478 Q59328394-C20DA766-A05F-46ED-8390-F1C2AEA42C34 @default.
- Q59328394 P577 Q59328394-8EE89F50-2A1A-406F-A980-972608EB0C37 @default.
- Q59328394 P6216 Q59328394-592994e9-b474-4af0-987d-196f3c42fe6a @default.
- Q59328394 P921 Q59328394-1AB0E615-0824-4974-B0DA-60E275E2C311 @default.
- Q59328394 P921 Q59328394-AD8AB5D6-C7F0-498C-9824-17E410DC384C @default.
- Q59328394 P921 Q59328394-BE61F676-E130-4141-9864-7CAC4638144D @default.
- Q59328394 P921 Q59328394-BE769F79-2868-44A3-8AEE-4D365BC97B45 @default.
- Q59328394 P932 Q59328394-4289CA8D-48C1-4468-9F43-C8A0E8EA10F3 @default.
- Q59328394 P356 OFY210.1244 @default.
- Q59328394 P1433 Q27725953 @default.
- Q59328394 P1476 "1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intra" @default.
- Q59328394 P2093 "Alexandra F Freeman" @default.
- Q59328394 P2093 "Amanda Urban" @default.
- Q59328394 P2093 "Benjamin Colton" @default.
- Q59328394 P2093 "Chris Lambros" @default.
- Q59328394 P2093 "Edmund Tramont" @default.
- Q59328394 P2093 "Elise Ferre" @default.
- Q59328394 P2093 "Lilian Kibathi" @default.
- Q59328394 P2093 "Maryellen McManus" @default.
- Q59328394 P2093 "Michail Lionakis" @default.
- Q59328394 P2093 "Parag Kumar" @default.
- Q59328394 P2093 "Raphael Mannino" @default.
- Q59328394 P2093 "Ruying Lu" @default.
- Q59328394 P275 Q24082749 @default.
- Q59328394 P304 "S435-S435" @default.
- Q59328394 P31 Q13442814 @default.
- Q59328394 P356 "10.1093/OFID/OFY210.1244" @default.
- Q59328394 P433 "suppl_1" @default.
- Q59328394 P478 "5" @default.
- Q59328394 P577 "2018-11-01T00:00:00Z" @default.
- Q59328394 P6216 Q50423863 @default.
- Q59328394 P921 Q273510 @default.
- Q59328394 P921 Q323936 @default.
- Q59328394 P921 Q412223 @default.
- Q59328394 P921 Q977090 @default.
- Q59328394 P932 "6253191" @default.